Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00969137 · ClinicalTrials.gov registry record · Phase 1
Sensitivity to Intravenous Nicotine: Genetic Moderators
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 213
- Enrollment target
NCT00969137: Completed Phase 1 study, sponsored by Yale University.
NCT00969137 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 213 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (255% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00969137, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 213 participants
- Enrollment target
Study Summary
To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including the ratings of "good effects" and "drug liking". We hypothesize that smokers with the AG/GG genotype for the OPRM1 A118G will have attenuated subjective-rewarding effects from IV nicotine when compared to those with AA genotype.
Interventions
- DRUG Nicotine
- DRUG saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2009-06-02 |
| Est. Completion | 2016-06-01 |
| Phase | Phase 1 |
What the finished NCT00969137 record still lists
NCT00969137 is an interventional study that assigns participants to a tested intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (255% higher).
The record links to 0 conditions, and to 2 interventions - of which Nicotine is the first listed.
NCT00969137 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00969137 about?
NCT00969137 is a clinical study titled "Sensitivity to Intravenous Nicotine: Genetic Moderators". To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including the ratings of "good effects" an...
What is the current status of trial NCT00969137?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 213 participants. The study started on 2009-06-02. Estimated completion is 2016-06-01.
What interventions are being tested in trial NCT00969137?
The interventions under investigation include: Nicotine (DRUG), saline (DRUG).
Who is sponsoring clinical trial NCT00969137?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00969137's enrollment target sits among peer trials
213 245th of 2000 higher than 1,756 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT06544655 · 213 participants · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI